KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Leases (2016 - 2025)

Nektar Therapeutics (NKTR) has 13 years of Current Leases data on record, last reported at $22.2 million in Q3 2025.

  • For Q3 2025, Current Leases rose 3.16% year-over-year to $22.2 million; the TTM value through Sep 2025 reached $22.2 million, up 3.16%, while the annual FY2024 figure was $19.9 million, 3.16% up from the prior year.
  • Current Leases reached $22.2 million in Q3 2025 per NKTR's latest filing, up from $22.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $22.2 million in Q3 2025 and bottomed at $15.8 million in Q1 2021.
  • Average Current Leases over 5 years is $19.4 million, with a median of $19.3 million recorded in 2023.
  • Peak YoY movement for Current Leases: increased 25.34% in 2021, then dropped 5.56% in 2023.
  • A 5-year view of Current Leases shows it stood at $17.4 million in 2021, then grew by 7.03% to $18.7 million in 2022, then rose by 3.17% to $19.3 million in 2023, then increased by 3.16% to $19.9 million in 2024, then grew by 11.65% to $22.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $22.2 million in Q3 2025, $22.0 million in Q2 2025, and $21.8 million in Q1 2025.